Mobosetinib is a targeted drug of several generations. What is its target?

Mobocertinib/Mobocertinib (Mobocertinib) is a third-generation targeted drug. It belongs to a class of drugs called tyrosine kinase inhibitors (TKIs), which are primarily used to treat non-small cell lung cancer (NSCLC) with EGFR Exon 20 mutations. Compared with the first and second generation targeted drugs, mobosetinib is more selective and specific and can effectively inhibit the growth of tumors caused by EGFR mutations. Therefore, it is considered a new generation of targeted therapy drugs.

The target of Mobosetinib is the epidermal growth factor receptor (Epidermal Growth Factor Receptor, EGFR), which is a transmembrane receptor that regulates signaling pathways in the control of cell proliferation. In cultured cell models, mobosetinib inhibited cell proliferation driven by different EGFR exon 20 insertion mutant variants at concentrations 1.5-10-fold lower than wild-type (WT)-EGFR signaling. In animal tumor transplant models, mobosetinib demonstrated antitumor activity against xenografts harboring EGFR exon 20 insertions of NPH or ASV.

Mobosetinib The original drug is currently on the market in China and has not yet been included in the medical insurance. SpecificationThe price of 40mg*112 pills per box is about 40,000 yuan, which is very expensive.The Hong Kong version of the original drug Specifications40mg*30 pills per box is priced at more than 7,000 yuan (the price may fluctuate due to exchange rates). Generic drugs of Mobotinib have also been put on the market for sale overseas. The drug ingredients are basically the same as those of the original drugs at home and abroad. For example, the production specifications of Laos Pharmaceutical Factory40mg*120 pills per boxThe pricemay be more than 4,000 yuan (the price may fluctuate due to the exchange rate), and the price is relatively cheap.